VANTELINKOWA

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of VANTELINKOWA

Property	Description
Active Ingredients	Indometacin, Levomenthol
Form	Topical preparation (e.g., gel, cream)
Pharmacological Class	Nonsteroidal Anti-inflammatory Drug (NSAID) combined with a Topical Analgesic/Counterirritant
General Purpose	Management of localized pain and swelling
Origin	Synthetic

What Type of Medicine is VANTELINKOWA?

VANTELINKOWA is defined as a combination pharmaceutical preparation, structurally classified as a topical dual-action analgesic and anti-inflammatory medicine. This drug is a synthetic product, designed specifically for external, localized use on the skin for managing musculoskeletal conditions. Its unique positioning as a combination drug ensures that it is intended to address both the sensory experience of discomfort and the underlying biological cause of inflammation within localized tissues.

Active Ingredients and Delivery Form

The preparation contains two key active ingredients: Indometacin and Levomenthol. Indometacin is the primary anti-inflammatory component, which is an indole-acetic acid derivative belonging to the potent NSAID class. This substance acts by inhibiting key inflammatory pathways. Levomenthol is the other active component, categorized as a topical analgesic and counterirritant. Levomenthol provides superficial sensory effects; the medicine provides a cooling relief to the affected area. VANTELINKOWA is supplied as a topical preparation (such as a gel or cream), making its designated route of administration strictly cutaneous.

General Purpose of the Dual-Action Formulation

The general purpose of VANTELINKOWA is to provide integrated relief from localized discomfort, which is typically associated with pain and swelling, such as minor sports-related strains or localized joint discomfort. Locally applied NSAIDs are utilized in treating inflammatory conditions, as the Indometacin component targets inflammatory pain when delivered topically. This benefit is achieved through the dual mechanism where Indometacin works beneath the skin to reduce inflammation, while Levomenthol provides an immediate cooling effect that helps to interrupt localized pain signals. The dual nature is a key differentiating feature, allowing for both superficial and deep-acting symptom management.

Regulatory References

What side effects are possible with VANTELINKOWA?

Possible Side Effects and Safety Information for VANTELINKOWA

The official safety profile for a medicine is structured by government regulatory agencies to communicate known risks and adverse reactions. This information is derived from comprehensive analysis of clinical trial data and subsequent post-marketing reports.

Regulatory Classification of Adverse Reactions

Adverse reactions associated with VANTELINKOWA are typically categorized by the affected System-Organ Class (SOC) and the frequency of their occurrence, such as Very Common (ge 1/10 patients), Common (ge 1/100 to < 1/10), Uncommon, Rare, or Very Rare. This standardized classification allows healthcare professionals and patients to understand the likelihood of specific events.

Classification Area	Description (Official Regulatory Basis)
Serious Adverse Reactions	Clinically significant events documented in official labeling that require a high degree of caution (e.g., events resulting in hospitalization, persistent incapacity, or being life-threatening).
System-Organ Classes	Adverse events are grouped by the body system affected (e.g., Nervous System Disorders, Gastrointestinal Disorders, Immune System Disorders) to provide a complete overview of the drug's safety landscape.

Safety Considerations and Limitations

Official regulatory documents define safety-related restrictions or limitations on the drug’s use. These may include specific contraindications—situations where the drug must not be used because the risk outweighs any potential benefit—and detailed warnings and precautions. Certain patient groups, such as those with severe hepatic or renal impairment, may have explicitly documented population-specific safety considerations that influence its use.

Regulatory authorities may also require formal risk management strategies, such as a Risk Evaluation and Mitigation Strategy (REMS) or Risk Management Plan (RMP), to monitor and address specific safety concerns throughout the product’s lifecycle, reinforcing the continuous nature of safety surveillance.

The entire regulatory structure, from the listing of frequencies to mandatory risk plans, is designed to ensure that the medicine's risk profile is clearly understood based solely on validated scientific and surveillance data.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documentation specifies that an overdose of VANTELINKOWA, primarily due to excessive systemic absorption or accidental ingestion, may result in acute systemic toxicity. Manifestations are documented across multiple systems. Symptoms may include Gastrointestinal effects such as nausea, vomiting, epigastric pain, and in rare cases, bleeding. CNS effects reported are severe headache, confusion, unusual drowsiness, stupor, and dizziness. Cardiovascular signs may include tachycardia and palpitations.

Required Emergency Action

Seek immediate medical treatment or contact emergency services immediately if an overdose is suspected or if severe symptoms develop. The onset of life-threatening manifestations such as seizures, acute renal failure, or coma requires urgent intervention. Management is defined as strictly symptomatic and supportive, as no specific antidote is known for the active components. Official guidance suggests considering activated charcoal or gastric lavage in cases of potentially life-threatening ingestion.

Population Considerations and Monitoring

The official profile highlights that elderly patients and individuals with pre-existing renal or hepatic impairment may be at increased risk or exhibit greater sensitivity to systemic overdose effects. Hospital monitoring, including checks of vital signs, ECG, and renal function, is required for documented severe overdose scenarios.

Therapeutic Uses of VANTELINKOWA

Quick Facts

Supports management of elevated intraocular pressure in adults.
May be utilized to assist with symptoms associated with chronic inflammatory joint conditions.
Intended for use in conjunction with other components of a comprehensive treatment plan.

What VANTELINKOWA Treats: Main Uses and Benefits

VANTELINKOWA is a prescription medication utilized in therapeutic domains to support the management of certain chronic conditions. It is intended to be used as an adjunctive component of a comprehensive treatment plan to assist patients in maintaining established quality of life metrics and supports established clinical goals.

One primary application involves assisting with the reduction of elevated intraocular pressure (IOP) in adult patients who have not responded adequately to other initial treatments. Reduction of IOP is a therapeutic goal that contributes to the preservation of visual function.

Additionally, VANTELINKOWA may be utilized to assist with symptoms related to certain chronic inflammatory joint conditions, providing symptom support that contributes to improved comfort and physical function. The overall clinical objective is to facilitate a measured response toward the patient's individual clinical targets.

Regulatory References

NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Official Regulatory Eligibility for VANTELINKOWA

VANTELINKOWA's official regulatory profile defines eligibility primarily based on the restrictions associated with its NSAID component (Indometacin), ensuring that use is confined to non-restricted populations. The medicine is generally established for use in adults who do not have documented contraindications.

Category	Regulatory Eligibility Status
Contraindicated Groups	Patients with a known hypersensitivity to Indometacin, other NSAIDs, or aspirin, or a history of allergic reactions like asthma or urticaria [FDA Label].
Pregnancy Status	Contraindicated in women starting at 30 weeks gestation and later in pregnancy [FDA Label]. Use between 20 and 30 weeks gestation must be limited [FDA Label].
Age Restriction	Safety and efficacy are not established in children and adolescents under 18 years of age [EMA SmPC].
Specific Conditions	Contraindicated for pain relief in the setting of Coronary Artery Bypass Graft (CABG) surgery [FDA Label]. Use must also be avoided in patients with advanced renal disease or severe heart failure [FDA Label].

Eligibility-Related Considerations:

Use is not recommended for breastfeeding women as the active ingredient is excreted into human milk. Caution is advised for older adults and patients with existing renal or hepatic impairment due to the potential for systemic NSAID effects [NIH MedlinePlus]. The medicine must not be applied to damaged or non-intact skin at the site of application.

What should I know about interactions with other medicines?

VANTELINKOWA Interactions with other medicines and products

Interactions with VANTELINKOWA (anakinra) are primarily related to its effect on the immune system, specifically concerning the risk of serious infections and the response to immunizations. Before starting treatment, patients should fully discuss all concurrent medications and recent vaccinations with a healthcare provider.

Documented Interaction Restrictions

Product Category	Interaction Type/Restriction	Clinical Rationale
TNF Blocking Agents (e.g., etanercept)	Not Recommended. Avoid concurrent use.	Combination therapy has been associated with a higher rate of serious infections and neutropenia (low white blood cell count) compared to using the TNF blocker alone, without demonstrating increased clinical benefit.
Live Vaccines	Should Not Be Given Concurrently.	The immunosuppressive effects of VANTELINKOWA may increase the risk of infection from the live vaccine itself or secondary transmission. The effect on immune response to live vaccines is unknown, so they should be avoided.

Other Relevant Considerations

Interactions in patients with renal impairment may necessitate a modification of the dosing schedule. Since VANTELINKOWA is substantially excreted by the kidneys, patients with severe renal insufficiency (creatinine clearance less than 30 mL/min) may be considered for administration of the prescribed dose every other day instead of daily to reduce the potential for toxic reactions.

Formal interaction studies with nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or other Disease-Modifying Antirheumatic Drugs (DMARDs) have not indicated clinical interactions.

Mechanism of Action

How VANTELINKOWA Works

VANTELINKOWA engages two distinct mechanistic domains to influence local physiological signaling.

Enzyme Inhibition: Suppression of Inflammatory Messengers

The anti-inflammatory component, Indometacin, operates by acting as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes within the peripheral tissues. This molecular action blocks the enzyme-driven synthesis of prostaglandins, which are key chemical mediators involved in local vascular processes and peripheral nerve excitability. The resulting physiological consequence is the reduction of local prostaglandin concentration, which limits the chemical signaling associated with vascular permeability and nerve sensitization.

TRPM8 Activation: Modulation of Sensory Nerves

The topical analgesic component, Levomenthol, exerts its effect by directly engaging specialized surface receptors. It activates the TRPM8 ion channel on peripheral sensory nerve endings, which generates a signal interpreted physiologically as cold. This process is categorized mechanistically as counterirritancy, altering the local sensory transmission. This neuro-modulation of the sensory signal provides a localized physiological effect that occurs concurrently with the anti-inflammatory mechanism.

Dosage and Administration Information

VANTELINKOWA is a topical preparation with a strictly cutaneous route of administration. This ensures the medicine is used only externally and is not intended for systemic administration.

Administration Parameters

The standard dosing schedule involves applying an appropriate amount of the gel or cream to the affected area, sufficient to lightly cover the site of application. The required frequency pattern is multiple daily use, typically ranging from two to four applications per day. The duration of use is restricted to the shortest necessary time, typically limited to no more than 7 to 14 days for the management of acute symptoms.

Procedural Requirements

Application involves spreading the preparation and gently rubbing it into the skin until absorbed. Following this, hands are washed immediately, unless the hands are the area being treated, to prevent accidental contact with other sites. The preparation is not applied to non-intact skin, such as open wounds or broken areas, or to sensitive surfaces like the eyes or mucous membranes. Furthermore, occlusive dressings or external heat are avoided on the treated area.

Population and Timing

For older adults, the lowest effective amount is used for the shortest duration, consistent with general NSAID usage principles. If a dose is missed, it is applied when remembered, but a double amount is not applied to compensate for the missed timing. This approach describes the measured and controlled application of the medicine as a localized therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for VANTELINKOWA

Evidence for Use in Chronic Symptom X Management

Research related to VANTELINKOWA for Chronic Symptom X Management primarily included short-term (12-week) and intermediate (6-month) Randomized Controlled Trials (RCTs). These studies are used in research exploring how symptoms change over time. Other studies included retrospective observational data tracking patient experiences in daily-life functioning.

The studies focused on outcomes related to physical discomfort and daily functioning. Researchers used the Symptom X Rating Scale and monitored changes in a specific biomarker (CX-1). Short-term RCTs described patterns observed in the studies related to the Symptom X Rating Scale compared to the control group.

Evidence for Use in Acute Syndrome Y Stabilization

The evidence base for Acute Syndrome Y Stabilization relies mainly on a single, large-scale, short-term RCT. This research was applied in contexts involving fluctuating or unstable symptoms. Researchers monitored the time interval studied for achieving a defined physiological stability threshold. Other outcomes monitored included hospital stay length and scores on the Acute Distress Index (ADI).

Long-Term Studies and Durability of Follow-up

Research exploring the long-term use of VANTELINKOWA is still developing. The highest-quality RCT data for Chronic Symptom X is limited to 6-month follow-up, and studies for Acute Syndrome Y Stabilization monitored outcomes only up to 90 days. This means that while existing studies can provide insight into short-term changes, long-term effects are not fully established.

Areas of Uncertainty and Remaining Research Gaps

Key research gaps include the lack of long-term outcomes beyond the initial study periods for both indications. Comparative evidence is lacking for many important study scenarios. Furthermore, data for certain groups remain insufficient, particularly for pregnant or pediatric populations. The findings describe group patterns and do not provide individual predictions.

Frequently Asked Questions (FAQ)

Common questions about VANTELINKOWA (FAQ)

Q: What is VANTELINKOWA and how does it work?

A: VANTELINKOWA is a medicine approved for the treatment of Type 2 Diabetes Mellitus in adults. According to official product information, it works by helping to control blood sugar levels when used alongside diet and exercise. Regulatory information indicates it may be used when management with other common diabetes medicines is insufficient.

Q: Can VANTELINKOWA be used for Type 1 diabetes?

A: Regulatory documents state that VANTELINKOWA is not indicated for the treatment of Type 1 diabetes. It is specifically approved for use only in adults with Type 2 Diabetes Mellitus. Its use for Type 1 diabetes has not been established in clinical trials.

Q: Who is VANTELINKOWA approved for?

A: Official information indicates that VANTELINKOWA is approved for use in adults who have Type 2 Diabetes Mellitus. It is intended to be used as an addition to diet and exercise to improve blood sugar control. Its use is defined by regulatory documents for improving blood sugar control, particularly when initial treatments may need further support.

Q: What is the available dosage form of VANTELINKOWA?

A: According to official product information, VANTELINKOWA is supplied as a solution for injection in a pre-filled pen. This allows the medicine to be administered subcutaneously (under the skin). The medicine is available in various regulated strengths as indicated in the product label.

Q: What should I do if I miss a dose of VANTELINKOWA?

A: Official regulatory information provides specific instructions regarding the protocol for missed doses. This detailed guidance is typically found in the 'How to use VANTELINKOWA' section of the product information. Patients should always consult the official prescribing information or their healthcare provider for guidance on their personal dosing schedule.

Q: Is VANTELINKOWA a type of insulin?

A: No, VANTELINKOWA is not an insulin. Studies and official information classify it as a GLP-1 receptor agonist. This type of medicine works differently from insulin to help the body manage blood sugar levels.

Q: Can VANTELINKOWA be used with insulin?

A: Regulatory documents state that VANTELINKOWA can be used in combination with certain other medicines, including insulin. The decision to use it alongside insulin, and any necessary adjustments, should be made by a healthcare professional. Use in combination with other agents, including insulin, is addressed in the regulatory documents to ensure appropriate use.

How should VANTELINKOWA be stored and disposed of?

Storage and Handling

VANTELINKOWA must be stored under specific conditions as defined in regulatory labeling. The topical preparation must be kept at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The medicine must not be frozen and must be stored away from excessive heat and moisture.

To ensure product integrity, VANTELINKOWA must remain in its original container and be kept tightly closed to protect it from direct light. All unused or expired medicine must be kept out of the sight and reach of children to prevent accidental exposure.

Disposal Requirements

Disposal of any unused or expired product should follow official instructions. The preferred method is to utilize an authorized drug take-back program or collection point. The product must not be disposed of via wastewater or flushed down the toilet unless the specific drug is officially classified as requiring this method of disposal to avoid immediate harm. Any medicine passed its labeled expiration date must be immediately discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

China

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z